Compounds > arterolane
Page last updated: 2024-08-02 17:09:21

arterolane

Description

arterolane: a trioxolane with antimalarial activity; structure in first source [MeSH]

Cross-References

ID SourceID
PubMed CID10475633
CHEMBL ID404431
CHEMBL ID221773
CHEMBL ID578577
CHEMBL ID1197433
CHEMBL ID580910
SCHEMBL ID13951812
SCHEMBL ID4547841
SCHEMBL ID11379522
SCHEMBL ID12612733
SCHEMBL ID10307589
CHEBI ID136054
MeSH IDM0472074

Synonyms (40)

Synonym
arterolane
oz277
arterolano
rbx11160
CHEBI:136054
rbx-11160
oz 277
n-(2-amino-2-methylpropyl)-2-[(1s,4s)-dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.1(3,7)]decan]-4-yl]acetamide
664338-39-0
arterolanum
CHEMBL404431
CHEMBL221773
oz-277
CHEMBL578577
CHEMBL1197433
3n1tn351vb ,
oz277 cpd
rbx 11160
unii-3n1tn351vb
arterolane [inn]
NCGC00274173-01
arterolane [who-dd]
dispiro(cyclohexane-1,3'-(1,2,4)trioxolane-5',2''-tricyclo(3.3.1.13,7)decane)-4-acetamide, n-(2-amino-2-methylpropyl)-, cis-
SCHEMBL13951812
SCHEMBL4547841
SCHEMBL11379522
SCHEMBL12612733
SCHEMBL10307589
CHEMBL580910
CS-0002648
HY-10852
VXYZBLXGCYNIHP-BBMJWGJISA-N
VXYZBLXGCYNIHP-CAGINOIPSA-N
n-(2-amino-2-methylpropyl)-2-((1r,3r,4''s,5r,5's,7r)-dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1''-cyclohexan]-4''-yl)acetamide
DTXSID50985095
oz 277;rbx 11160
AT25294
MS-26573
n-(2-amino-2-methylpropyl)-2-{dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1''-cyclohexane]-4''-yl}acetamide
AKOS040741167

Bioassays (128)

Assay IDTitleYearJournalArticle
AID728700Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected mouse assessed as reduction in parasitemia at 30 mg/kg, po measured on day 3 postinfection relative to control2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID520092Induction of heme alkylation of Fe(II) heme assessed as loss of heme at 10 uM in presence of 50% ACN-H2O with excess sodium dithionite under argon at 20 degC by spectrophotometry2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804		Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
AID1457833Antiplasmodial activity against Plasmodium falciparum Cam3.2_rev infected in human RBC assessed as time required to reduce early ring stage parasite viability by 50% by SYTO 61-staining-based flow cytometry2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID422400Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 9002009Journal of natural products, Feb-27, Volume: 72, Issue:2
ISSN: 1520-6025		The marine sponge Diacarnus bismarckensis as a source of peroxiterpene inhibitors of Trypanosoma brucei, the causative agent of sleeping sickness.
AID366932Antiplasmodial activity as survival in Plasmodium berghei ANKA infected BALB/c mice (Mus musculus) at 30 mg/kg peroral dose2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
ISSN: 1520-4804		Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells.
AID341601Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB9002007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID572089Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID560761Stability of compound in presence of oxyhemoglobin assessed as pseudo-first order degradation rate constant at 10 uM at 20degC over 24 hrs2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596		Stability of peroxide antimalarials in the presence of human hemoglobin.
AID1777173Intrinsic clearance in mouse liver microsome by LC-MS/MS analysis2021ACS medicinal chemistry letters, Jul-08, Volume: 12, Issue:7
ISSN: 1948-5875		Enantioselective Synthesis and Profiling of Potent, Nonlinear Analogues of Antimalarial Tetraoxanes E209 and N205.
AID572078Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 1:1 ratio of compound to 4-oxo-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572074Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 3:1 ratio of compound to 4-hydroxy-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID1457817Antiplasmodial activity against Plasmodium berghei infected in Swiss Webster mouse assessed as cure rate at 4 mg/kg/day administered for 4 days via oral gavage starting at 1 hr post infection measured after 30 days relative to control2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID341600Antiplasmodial activity against Plasmodium falciparum NF542007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1457810Antiplasmodial activity against Plasmodium falciparum Cam3.2 infected in human RBC assessed as time required to reduce early ring stage parasite viability by 50% by SYTO 61-staining-based flow cytometry2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID572091Antimalarial activity against Plasmodium falciparum K1 by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572084Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of deoxyartemisinin2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID1457816Antiplasmodial activity against Plasmodium berghei infected in Swiss Webster mouse assessed as increase in cure rate administered for 4 days via oral gavage starting at 1 hr post infection measured after 30 days2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID1625265Antimalarial activity against GFP-transfected Plasmodium berghei ANKA infected in mouse assessed as reduction in parasitemia at 30 mg/kg, po administered on day 1 post infection measured on day 3 post infection2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
ISSN: 1520-4804		Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID728701Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in mouse at 30 mg/kg, po2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID572081Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 1:1 ratio of compound to 2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572075Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 1:1 ratio of compound to 4-hydroxy-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID560760Stability of compound in presence water assessed as pseudo-first order degradation rate constant at 10 uM at 20degC over 24 hrs2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596		Stability of peroxide antimalarials in the presence of human hemoglobin.
AID728696Dissociation constant, pKa of the compound2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID1625266Oral bioavailability in rat at 3 mg/kg2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
ISSN: 1520-4804		Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID1457815Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human RBC after 48 hrs by YOYO-1 staining-based flow cytometry method2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID572083Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of carbaOZ2772010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID447027Antimalarial activity against Plasmodium falciparum NF542009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
ISSN: 1464-3405		Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.
AID632148Binding affinity to Plasmodium falciparum calcium-transporting ATPase2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
ISSN: 1520-4804		Investigating the antimalarial action of 1,2,4-trioxolanes with fluorescent chemical probes.
AID520094Induction of heme alkylation of Fe(II) heme assessed as adduct A472 absorbance change at completion of reaction at 10 uM in presence of 50% ACN-H2O with excess sodium dithionite under argon at 20 degC by spectrophotometry2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804		Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
AID572082Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 1:3 ratio of compound to 2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID320102Distribution coefficient, log D of the compound2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
ISSN: 1464-3405		Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277.
AID1625264Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 after 24 hrs in presence of hypoxanthine2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
ISSN: 1520-4804		Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID620219Induction of oxyl radical formation from reaction with ferrous salt in the presence of 2,2,6,6-tetramethyl-1-piperidine-1-oxyl after 24 hrs by spin-trapping and LC/MS analysis2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
ISSN: 1520-4804		Comparison of the reactivity of antimalarial 1,2,4,5-tetraoxanes with 1,2,4-trioxolanes in the presence of ferrous iron salts, heme, and ferrous iron salts/phosphatidylcholine.
AID341607Antimicrobial activity against Babesia divergens 42012007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID728702Antimalarial activity against chloroquine-resistant Plasmodium falciparum K12013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID341606Antimicrobial activity against Babesia divergens 1903B2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID572080Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 3:1 ratio of compound to 2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID341602Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C42007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID572069Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 1:1 ratio of compound to 4-amino-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572068Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 3:1 ratio of compound to 4-amino-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID632150Antimalarial activity against Plasmodium falciparum K1 infected in human A-positive type erythrocytes after 72 hrs by SRB assay2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
ISSN: 1520-4804		Investigating the antimalarial action of 1,2,4-trioxolanes with fluorescent chemical probes.
AID447026Antimalarial activity against Plasmodium falciparum K12009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
ISSN: 1464-3405		Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.
AID728692AUC (0 to 24 hrs) in mouse at 30 mg/kg, po by LC-MS analysis2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID572073Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 1:3 ratio of compound to 4-carboxy-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID728699Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected mouse assessed as survival at 30 mg/kg, po2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID572086Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 4-carboxy-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572090Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572067Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence 1:3 ratio of compound to deoxyartemisinin2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572088Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 4-oxo-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572087Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 4-hydroxy-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID728695Lipophilicity, log D of the compound at pH 7.42013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID572066Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence 1:1 ratio of compound to deoxyartemisinin2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID728691Plasma concentration in Swiss outbred mouse at 30 mg/kg, po at 24 hrs by LC-MS analysis2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID341604Antimicrobial activity against Giardia duodenalis WB2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID572071Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 3:1 ratio of compound to 4-carboxy-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID728694Intrinsic clearance in mouse liver microsomes at 1 uM after 60 mins by LC-MS analysis2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID572092Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence 1:1 ratio of compound to carbaOZ2772010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID1777174Intrinsic clearance in mouse liver microsome assessed as half life by LC-MS/MS analysis2021ACS medicinal chemistry letters, Jul-08, Volume: 12, Issue:7
ISSN: 1948-5875		Enantioselective Synthesis and Profiling of Potent, Nonlinear Analogues of Antimalarial Tetraoxanes E209 and N205.
AID572085Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 4-amino-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID341603Antileishmanial activity against Leishmania donovani MHOM-ET-67/L82 amastigotes by axenic assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID430464Induction of heme alkylation measured within 30 seconds by visible spectrophotometry2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
ISSN: 1464-3405		Spiroadamantyl 1,2,4-trioxolane, 1,2,4-trioxane, and 1,2,4-trioxepane pairs: relationship between peroxide bond iron(II) reactivity, heme alkylation efficiency, and antimalarial activity.
AID366936Antiplasmodial activity as reduced parasitaemia in Plasmodium berghei ANKA infected BALB/c mice (Mus musculus) at 30 mg/kg peroral dose2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
ISSN: 1520-4804		Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells.
AID728698Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected mouse assessed as cured animal at 30 mg/kg, po measured on day 30 postinfection2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID341612Inhibition of Plasmodium falciparum ATP62007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID320101Antimalarial activity against Plasmodium falciparum K12008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
ISSN: 1464-3405		Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277.
AID572076Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 1:3 ratio of compound to 4-hydroxy-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID1457811Half life in mouse liver microsomes2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID572093Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence 3:1 ratio of compound to carbaOZ2772010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572070Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 1:3 ratio of compound to 4-amino-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID1457812Intrinsic clearance in mouse liver microsomes assessed per mg of protein2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID341599Antiplasmodial activity against Plasmodium falciparum K12007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID560762Stability of compound in presence of methoxyhemoglobin assessed as pseudo-first order degradation rate constant at 10 uM at 20degC over 24 hrs2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596		Stability of peroxide antimalarials in the presence of human hemoglobin.
AID772516Antimalarial activity against mature gametocytic stage of Plasmodium falciparum assessed as inhibition of mature gamete exflagellation at 10 uM incubated for 24 hrs prior to exflagellation induction at 21 degC measured after 20 mins by microscopic analysi2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
ISSN: 1520-4804		Using genetic methods to define the targets of compounds with antimalarial activity.
AID728693Half life in mouse whole blood2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID341605Antimicrobial activity against Giardia duodenalis G12007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID572079Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 1:3 ratio of compound to 4-oxo-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID1457832Metabolic stability in mouse liver microsomes in absence of NADPH2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID1457818Antiplasmodial activity against Plasmodium berghei infected in Swiss Webster mouse assessed as cure rate at 1 mg/kg/day administered for 4 days via oral gavage starting at 1 hr post infection measured after 30 days relative to control2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID728697Partition coefficient, log P of the compound2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
ISSN: 1520-4804		Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID341598Antimicrobial activity against Neospora caninum up to 1 ug/ml2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
ISSN: 0066-4804		Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1777163Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 incubated for 72 hrs by spectrophotometry based parasite lactate dehydrogenase assay2021ACS medicinal chemistry letters, Jul-08, Volume: 12, Issue:7
ISSN: 1948-5875		Enantioselective Synthesis and Profiling of Potent, Nonlinear Analogues of Antimalarial Tetraoxanes E209 and N205.
AID1457814Kinetic solubility of the compound in PBS at pH 7.42017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID572077Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 3:1 ratio of compound to 4-oxo-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID1457820Antiplasmodial activity against Plasmodium berghei infected in Swiss Webster mouse assessed as cure rate at 10 mg/kg/day administered for 4 days via oral gavage starting at 1 hr post infection measured after 30 days relative to control2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID572064Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence 1:3 ratio of compound to carbaOZ2772010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID520093Antimalarial activity against chloroquine-resistant Plasmodium falciparum K12008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804		Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
AID572072Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 1:1 ratio of compound to 4-carboxy-2,2,6,6,-tetramethyl-1-piperidinyloxy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572065Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence 3:1 ratio of compound to deoxyartemisinin2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596		Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID1457819Antiplasmodial activity against Plasmodium berghei infected in Swiss Webster mouse assessed as cure rate at 6 mg/kg/day administered for 4 days via oral gavage starting at 1 hr post infection measured after 30 days relative to control2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804		Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID748927Half life in Sprague-Dawley rat at 3 mg/kg, iv2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
ISSN: 1464-3405		Recent advances in malaria drug discovery.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
ISSN: 1464-3391		Highly predictive and interpretable models for PAMPA permeability.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
ISSN: 2045-2322		Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
ISSN: 1464-3391		Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1873043Antimalarial activity against chloroquine sensitive Plasmodium falciparum NF54 assessed as inhibition of parasite growth by [3H]-hypoxanthine incorporation assay2022European journal of medicinal chemistry, Jul-05, Volume: 237ISSN: 1768-3254Spiral molecules with antimalarial activities: A review.
AID1496712Antimalarial activity against Plasmodium berghei infected in mouse assessed as reduction in parasitemia at 30 mg/kg, po administered as single dose measured on day 3 relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
ISSN: 1464-3391		Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
AID1873042Antimalarial activity against chloroquine resistant Plasmodium falciparum K1 assessed as inhibition of parasite growth by [3H]-hypoxanthine incorporation assay2022European journal of medicinal chemistry, Jul-05, Volume: 237ISSN: 1768-3254Spiral molecules with antimalarial activities: A review.
AID1496713Antimalarial activity against Plasmodium berghei infected in mouse assessed as mouse mean survival days at 30 mg/kg, po administered as single dose2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
ISSN: 1464-3391		Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
AID1440472In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as as protection against infection at 100 mg/kg, po single dose administered 48 hrs prior to infection2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440469Plasma concentration in FVB mouse at 30 mg/kg, administered through oral gavage as single dose measured after 48 hrs post dose by LC-MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440463Intrinsic clearance in mouse liver microsomes at 1 uM by LC/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440475In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as mouse survival at 100 mg/kg, po single dose administered 96 hrs prior to infection (Rvb = 6 to 7 days)2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1276198Stability in human blood after 240 mins by LC/MS analysis2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
ISSN: 1948-5875		Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1440464Intrinsic clearance in rat liver microsomes at 1 uM by LC/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440482In vivo antimalarial activity against GFP-transfected Plasmodium berghei ANKA infected in mouse assessed as mean survival days at 30 mg/kg, po administered as single dose measured after 30 days post infection by flow cytometric analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440468Cmax in FVB mouse at 30 mg/kg, administered through oral gavage as single dose by LC-MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440483In vivo antimalarial activity against GFP-transfected Plasmodium berghei ANKA infected in mouse assessed as parasitemia cured mouse at 30 mg/kg, po administered as single dose measured after 30 days post infection by flow cytometric analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440457Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 18 hrs by liquid scintillation counting2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440476In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as as protection against infection at 100 mg/kg, po single dose administered 96 hrs prior to infection2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440462Intrinsic clearance in human liver microsomes at 1 uM by LC/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1276199Ratio of drug level in human blood to plasma2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
ISSN: 1948-5875		Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1276196Stability in human plasma after 240 mins by LC/MS analysis2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
ISSN: 1948-5875		Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1440477In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as fold change in mouse survival at 100 mg/kg, po single dose administered 72 hrs prior to infection relative to control2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440458Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 18 hrs by liquid scintillation counting2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440470In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as mouse survival at 100 mg/kg, po single dose administered 48 hrs prior to infection (Rvb = 6 to 7 days)2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440466Kinetic solubility of the compound in water after 30 mins by nephelometric analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440465Intrinsic clearance in dog liver microsomes at 1 uM by LC/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1276195Antiplasmodium activity against Plasmodium falciparum W2 by flow cytometry2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
ISSN: 1948-5875		Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1440471In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as mouse survival at 30 mg/kg, po single dose administered 24 hrs prior to infection (Rvb = 6 to 7 days)2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440467AUC (0 to infinity) in FVB mouse at 30 mg/kg, administered through oral gavage as single dose by LC-MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440473In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as mouse survival at 100 mg/kg, po single dose administered 72 hrs prior to infection (Rvb = 6 to 7 days)2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440474In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as as protection against infection at 100 mg/kg, po single dose administered 72 hrs prior to infection2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1440455In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as protection against infection at 30 mg/kg, po single dose administered 24 hrs prior to infection2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
ISSN: 1520-4804		Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID279859Inhibition of Plasmodium falciparum ATP6 expressed in Xenopus laevis oocytes2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
ISSN: 0066-4804		Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).
AID279860Antimalarial activity against Plasmodium falciparum NF54 within 48 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
ISSN: 0066-4804		Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).
AID279857Inhibition of rabbit muscle SERCA at 100 uM2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
ISSN: 0066-4804		Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).
AID279855Inhibition of Plasmodium falciparum ATP6 expressed in Xenopus laevis oocytes at 50 uM2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
ISSN: 0066-4804		Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).
AID279858Inhibition of Plasmodium falciparum HT expressed in Xenopus laevis oocytes assessed as D-[U-14C]glucose uptake at 50 uM2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
ISSN: 0066-4804		Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).
AID279861Abrogation of Plasmodium falciparum ATP6 inhibition expressed in Xenopus laevis oocytes at 10 uM in presence of 100 uM desferioxamine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
ISSN: 0066-4804		Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).

Research

Studies (59)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's20 (33.90)29.6817
2010's32 (54.24)24.3611
2020's7 (11.86)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (16.67%)5.53%
Reviews4 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other46 (76.67%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
fosmidomycin
1
hydroxamic acid;
phosphonic acids		antimicrobial agent;
bacterial metabolite;
EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor		201620168.0low000010
b 844-39
1
diarylmethane201720177.0low000010
pk 11195
3
aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes		antineoplastic agent201720205.3low000030
jtv519
3
201720205.3high000030
albendazole
1
aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator		2007200717.0low000100
alprazolam
3
organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic		201720205.3low000030
amiodarone
1
1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug201720177.0low000010
dan 2163
3
aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic		201720205.3low000030
amlexanox
3
monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug		201720205.3low000030
astemizole
3
benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist		201720205.3low000030
benzbromarone
3
1-benzofurans;
aromatic ketone		uricosuric drug201720205.3low000030
bisindolylmaleimide i
3
201720205.3low000030
bufexamac
3
aromatic ether;
hydroxamic acid		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug		201720205.3low000030
cadralazine
3
organic molecular entity201720205.3low000030
carvedilol
2
carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent		201920204.5low000020
cetirizine
2
ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic		201920204.5low000020
chlorcyclizine
3
diarylmethane201720205.3low000030
chloroquine
4
aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug		201320218.0low000031
ci 994
3
acetamides;
benzamides;
substituted aniline		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor		201720205.3low000030
cyclosporine
2
201720205.5high000020
diclofenac
1
amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		201720177.0low000010
fenbendazole
3
aryl sulfide;
benzimidazoles;
carbamate ester		antinematodal drug201720205.3low000030
berotek
1
resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent		201720177.0low000010
furafylline
1
oxopurine201820186.0low000010
go 6976
3
indolocarbazole;
organic heterohexacyclic compound		EC 2.7.11.13 (protein kinase C) inhibitor201720205.3low000030
haloperidol
3
aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist		201720205.3low000030
miltefosine
1
phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor		2007200717.0low000100
homochlorocyclizine
3
diarylmethane201720205.3low000030
hydroxyzine
3
hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist		201720205.3low000030
ifenprodil
3
piperidines201720205.3low000030
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone
3
naphthalenes201720205.3medium000030
ketamine
3
cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic		201720205.3low000030
ketoconazole
1
dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine		201820186.0low000010
ketoprofen
3
benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic		201720205.3low000030
mebendazole
3
aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator		201720205.3low000030
mephenesin
3
aromatic ether;
glycerol ether		201720205.3low000030
midazolam
1
imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative		201720177.0low000010
niclosamide
3
benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor		201720205.3low000030
oxibendazole
3
benzimidazoles;
carbamate ester		201720205.3low000030
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine
3
201720205.3low000030
pentamidine
1
aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic		2009200915.0low000100
perphenazine
3
N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug		201720205.3low000030
pimobendan
3
benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent		201720205.3low000030
ag 1879
3
aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine		beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector		201720205.3low000030
primaquine
1
aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial2013201311.0low000010
pyrimethamine
2
aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor		2013201311.0low000020
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one
2
indoles201720205.5medium000020
ro 31-8220
3
imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor201720205.3low000030
ropinirole
3
indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist		201720205.3low000030
vorinostat
3
dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor		201720205.3low000030
sulfaphenazole
1
primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor		201820186.0low000010
2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
2
stilbenoid201720205.5high000020
trifluperidol
1
aromatic ketone201720177.0low000010
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
3
aromatic primary alcohol;
furans;
indazoles		antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent		201720205.3low000030
zotepine
3
dibenzothiepine;
tertiary amino compound		alpha-adrenergic drug;
second generation antipsychotic;
serotonergic drug		201720205.3low000030
methylene blue
1
organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer		2013201311.0low000010
colchicine
3
alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen		201720205.3low000030
benziodarone
3
aromatic ketone201720205.3low000030
methylene chloride
1
chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant		2009200915.0low000100
cyclizine
1
N-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic		201920195.0low000010
trehalose
3
trehaloseEscherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		201720205.3low000030
triclocarban
3
dichlorobenzene;
monochlorobenzenes;
phenylureas		antimicrobial agent;
antiseptic drug;
disinfectant;
environmental contaminant;
xenobiotic		201720205.3low000030
4-tert-octylphenol
3
alkylbenzene201720205.3low000030
cycloguanil
1
triazinesantifolate;
antiinfective agent;
antimalarial;
antiparasitic agent;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor		2013201311.0low000010
ethamivan
3
methoxybenzenes;
phenols		201720205.3low000030
methysergide
3
ergoline alkaloid201720205.3low000030
emetine
3
isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor		201720205.3low000030
melarsoprol
1
triazines2007200717.0low000100
podophyllotoxin
3
furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator		201720205.3low000030
erythromycin
1
cyclic ketone;
erythromycin		201620168.0low000010
etonitazene
3
201720205.3low000030
clothiapine
3
dibenzothiazepine201720205.3low000030
benperidol
3
aromatic ketone201720205.3low000030
7-hydroxychlorpromazine
3
phenothiazines201720205.3medium000030
sulfadoxine
1
pyrimidines;
sulfonamide		antibacterial drug;
antimalarial		2013201311.0low000010
camptothecin
3
delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite		201720205.3low000030
thenalidine
3
dialkylarylamine;
tertiary amino compound		201720205.3medium000030
decoquinate
1
2013201311.0low000010
bromocriptine
3
indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist		201720205.3low000030
benzonidazole
1
C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug2007200717.0low000100
dexchlorpheniramine
3
chlorphenamine201720205.3low000030
dv 1006
3
201720205.3medium000030
climbazole
3
aromatic ether;
hemiaminal ether;
imidazoles;
ketone;
monochlorobenzenes		201720205.3low000030
mefloquine
5
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial201320179.8low000050
triadimenol
3
aromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite		201720205.3medium000030
amonafide
3
isoquinolines201720205.3low000030
flupirtine
3
aminopyridine201720205.3low000030
chaetochromin
3
201720205.3medium000030
enoximone
3
aromatic ketone201720205.3low000030
aripiprazole
3
aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist		201720205.3low000030
aloxistatin
1
epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide		anticoronaviral agent;
cathepsin B inhibitor		201920195.0low000010
indocate
3
201720205.3medium000030
N(4)-acetylsulfathiazole
3
1,3-thiazoles;
acetamides;
sulfonamide		marine xenobiotic metabolite201720205.3high000030
cyclizine hydrochloride
2
201720205.5medium000020
2,3-trimethylene-4-quinazolone
3
quinazolines201720205.3medium000030
artemisinin
1
organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite		201520159.0low000010
artemether
5
artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial2008201313.6low000320
1,3-dimethyluric acid
3
oxopurinemetabolite201720205.3low000030
danofloxacin
3
quinolines201720205.3low000030
nitrefazole
3
imidazoles201720205.3medium000030
methotrimeprazine
3
phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist		201720205.3low000030
honokiol
3
biphenyls201720205.3low000030
9-methoxyellipticine
3
201720205.3low000030
3-aminophenoxazone
3
phenoxazine201720205.3low000030
3-deazaneplanocin
3
201720205.3low000030
tryptanthrine
3
alkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound		201720205.3low000030
atovaquone
3
hydroxy-1,2-naphthoquinone2007201612.0low000120
2-chlorodiazepam
3
201720205.3medium000030
Polycartine B
3
phenazines201720205.3high000030
aminoquinuride dihydrochloride
3
201720205.3high000030
thioproperazine mesylate
3
phenothiazines201720205.3medium000030
n(6)-(delta(2)-isopentenyl)adenine
3
6-isopentenylaminopurinecytokinin201720205.3low000030
4-methyl-N-(phenylmethyl)benzenesulfonamide
3
sulfonamide201720205.3medium000030
zpck
2
201920204.5low000020
sr141716
3
amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist		201720205.3low000030
(6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide
2
aromatic ketone201720205.5high000020
pyronaridine
1
aminoquinoline2013201311.0low000010
fingolimod
3
aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist		201720205.3low000030
tesmilifene
3
diarylmethane201720205.3low000030
tafenoquine
1
(trifluoromethyl)benzenes;
aminoquinoline;
aromatic ether;
primary amino compound;
secondary amino compound		2013201311.0low000010
sr 27897
3
indolyl carboxylic acid201720205.3low000030
piperaquine
2
aminoquinoline;
N-arylpiperazine;
organochlorine compound		antimalarial2013201311.0low000020
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine
3
leucine derivative201720205.3low000030
norketamine
3
organochlorine compound201720205.3low000030
indatraline
2
indanes201920204.5low000020
methotrexate
3
dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent		201720205.3low000030
salvinorin a
1
organic heterotricyclic compound;
organooxygen compound		metabolite;
oneirogen		201920195.0low000010
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide
3
201720205.3low000030
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide
3
phenylindole201720205.3low000030
l 741626
3
piperidines201720205.3low000030
tempol
1
aminoxyls;
hydroxypiperidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
catalyst;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
radical scavenger		2010201014.0low000100
dx 8951
3
pyranoindolizinoquinoline201720205.3low000030
tipifarnib
3
imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor		201720205.3low000030
cyc 202
3
2,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		201720205.3low000030
3-(n-acetyl-n-hydroxy)aminopropylphosphonic acid
1
phosphonoacetic acid201620168.0low000010
avasimibe
3
monoterpenoid201720205.3low000030
speciophylline
1
indolizines202220222.0medium000001
erysodine
1
aromatic ether;
diether;
Erythrina alkaloid;
organic heterotetracyclic compound;
phenols		antiparasitic agent;
nicotinic antagonist;
phytogenic insecticide		202220222.0low000001
l 163191
3
201720205.3low000030
dizocilpine
3
secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist		201720205.3low000030
s-benzylcysteine
3
S-aryl-L-cysteine zwitterion201720205.3high000030
chelidonine
3
alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid		201720205.3low000030
lapatinib
3
furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor		201720205.3low000030
roxindole
3
indolesalpha-adrenergic antagonist;
serotonergic drug		201720205.3low000030
conidendrin
3
201720205.3high000030
Porfiromycine
3
mitomycin201720205.3high000030
nsc 95397
3
1,4-naphthoquinones201720205.3low000030
4-methyl-2-quinazolinamine
3
201720205.3high000030
2-glycineamide-5-chlorophenyl-2-pyrryl ketone
3
201720205.3high000030
niguldipine hydrochloride
2
201920204.5medium000020
2,5-bis(5-hydroxymethyl-2-thienyl)furan
3
thiophenes201720205.3low000030
ritonavir
3
1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic		201720205.3low000030
bardoxolone methyl
1
cyclohexenones201920195.0low000010
Destruxin B
3
cyclodepsipeptide201720205.3high000030
tosylphenylalanyl chloromethyl ketone
3
alpha-chloroketone;
sulfonamide		alkylating agent;
serine proteinase inhibitor		201720205.3low000030
quinidine
1
cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker		201820186.0low000010
mefloquine hydrochloride
1
2009200915.0low000100
trichostatin a
1
antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector		201920195.0low000010
thapsigargin
1
butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor		2007200717.0low000100
clindamycin
1
201620168.0low000010
zithromax
1
macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic		201620168.0low000010
artenimol
3
201720224.0low000012
sitafloxacin
1
fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic		201920195.0low000010
2'-c-methylcytidine
3
201720205.3low000030
triacetoneamine-n-oxyl
1
aminoxyls;
piperidones		radical scavenger2010201014.0low000100
jp-1302
3
201720205.3medium000030
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one
3
benzodiazepine201720205.3high000030
tenatoprazole
3
imidazopyridine201720205.3low000030
s 1033
3
(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor		201720205.3low000030
5-[(2-fluoroanilino)methyl]-8-quinolinol
3
hydroxyquinoline201720205.3high000030
benidipine hydrochloride
2
201720205.5low000020
benidipine
1
201920195.0low000010
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one
3
quinazolines201720205.3high000030
chlorprothixene
3
chlorprothixene201720205.3medium000030
jrf 12
3
201720205.3low000030
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester
3
methoxybenzenes;
substituted aniline		201720205.3high000030
3-hydroxypyridine, sodium salt
3
201720205.3high000030
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide
3
naphthalenecarboxamide201720205.3medium000030
5-[(2-bromoanilino)methyl]-8-quinolinol
3
hydroxyquinoline201720205.3high000030
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide
3
201720205.3medium000030
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline
3
aromatic amine201720205.3high000030
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide
3
piperidinecarboxamide201720205.3high000030
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol
3
hydroxyquinoline201720205.3high000030
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide
3
acetamides;
anilide		201720205.3high000030
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide
3
aromatic amide;
thiophenes		201720205.3high000030
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone
3
dimethoxybenzene201720205.3high000030
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide
3
aromatic amide201720205.3high000030
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide
3
aromatic ether201720205.3high000030
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione
3
maleimides201720205.3high000030
Src Inhibitor-1
3
aromatic ether;
polyether;
quinazolines;
secondary amino compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor201720205.3high000030
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one
3
dimethoxybenzene201720205.3high000030
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide
3
quinolines201720205.3high000030
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3
pyrroles201720205.3high000030
tempo
1
aminoxyls;
piperidines		catalyst;
ferroptosis inhibitor;
radical scavenger		2010201014.0low000100
bi-78d3
3
aryl sulfide201720205.3medium000030
kartogenin
3
201720205.3low000030
toremifene
1
aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator		201920195.0low000010
quinine
1
cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic		2013201311.0low000010
vx-745
3
aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor		201720205.3low000030
dasatinib
3
1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor		201720205.3low000030
tempo carboxylic acid
1
aminoxyls;
piperidinemonocarboxylic acid		MRI contrast agent;
radical scavenger;
spin label		2010201014.0medium000100
zd 6474
3
aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor		201720205.3low000030
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
2
indoles201920204.5high000020
nih-12848
3
201720205.3high000030
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide
3
quinazolines201720205.3high000030
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone
3
benzimidazoles201720205.3high000030
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile
3
imidazopyridine201720205.3high000030
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
3
aromatic ketone201720205.3high000030
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester
3
oxopurine201720205.3high000030
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester
3
organonitrogen compound;
organosulfur compound		201720205.3high000030
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide
3
quinolines201720205.3high000030
LSM-1924
3
organic heterotricyclic compound;
organooxygen compound		201720205.3high000030
ferrostatin-1
3
ethyl ester;
primary arylamine;
substituted aniline		antifungal agent;
antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radiation protective agent;
radical scavenger		201720205.3low000030
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine
3
C-nitro compound201720205.3high000030
rabeprazole(1-)
2
organic nitrogen anion201920204.5high000020
ncgc00099374
3
201720205.3high000030
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide
3
benzamides201720205.3high000030
luteolin
3
3'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist		201720205.3low000030
cyclosporine
1
201920195.0low000010
kaempferol
3
7-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite		201720205.3low000030
genistein
3
7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor		201720205.3low000030
mycophenolate mofetil
3
carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug		201720205.3medium000030
bruceantin
3
triterpenoid201720205.3low000030
chrysin
3
7-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite		201720205.3low000030
daidzein
3
7-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite		201720205.3low000030
neticonazole
3
aromatic ether;
benzenes;
conazole antifungal drug;
enamine;
imidazole antifungal drug;
imidazoles;
methyl sulfide		antifungal drug;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor		201720205.3medium000030
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine
3
endocannabinoid;
N-acylethanolamine 22:6		201720205.3medium000030
n-oleoylethanolamine
3
endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1		EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist		201720205.3low000030
alpha-zearalenol
3
macrolide201720205.3high000030
su 9516
3
201720205.3low000030
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
3
triazolopyrimidines201720205.3high000030
sb 277011
3
201720205.3low000030
sb 223412
3
201720205.3low000030
sr 59230a
3
tetralins201720205.3high000030
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide
3
pyrimidines201720205.3medium000030
kn 62
3
piperazines201720205.3low000030
erysovine
1
202220222.0medium000001
erythraline
1
alkaloid202220222.0medium000001
MeJA
3
Jasmonate derivatives201720205.3high000030
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)-
3
201720205.3high000030
pd 161570
3
201720205.3medium000030
su 11248
1
monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist		201720177.0low000010
palbociclib
3
aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		201720205.3low000030
jnj-7706621
3
sulfonamide201720205.3low000030
virginiamycin factor s1
3
cyclodepsipeptide;
macrolide antibiotic		antibacterial drug;
bacterial metabolite		201720205.3high000030
fenoterol
2
hydrobromidebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent		201920204.5low000020
xib 4035
3
201720205.3high000030
gw-5074
1
201920195.0low000010
proguanil
1
biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor		2013201311.0low000010
psammaplin a
1
2009200915.0low000100
lumefantrine
1
fluorenes;
monochlorobenzenes;
secondary alcohol;
tertiary amine		antimalarial2013201311.0low000010
belotecan
3
pyranoindolizinoquinoline201720205.3low000030
norgestimate
3
ketoxime;
steroid ester;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive		201720205.3high000030
b 43
3
aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector		201720205.3medium000030
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine
3
201720205.3medium000030
methiazole
3
benzimidazoles;
carbamate ester		201720205.3high000030
sb 218795
3
quinolines201720205.3medium000030
bvt.948
3
201720205.3high000030
fk 866
1
benzamides;
N-acylpiperidine		201920195.0low000010
a 38503
3
201720205.3medium000030
artesunate
6
artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer		2007201812.0low000240
parthenolide
2
sesquiterpene lactonedrug allergen;
inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug		201720196.0medium000020
krn 633
3
201720205.3medium000030
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid
3
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound		201720205.3high000030
gw 501516
3
1,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound		carcinogenic agent;
PPARbeta/delta agonist		201720205.3low000030
dolastatin 10
3
1,3-thiazoles;
tetrapeptide		animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent		201720205.3low000030
spc-839
3
201720205.3low000030
midostaurin
3
benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor		201720205.3low000030
valnemulin
2
201920204.5medium000020
nu 7026
3
organic heterotricyclic compound;
organooxygen compound		201720205.3low000030
osi 930
3
aromatic amide201720205.3medium000030
ticagrelor
3
aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines		P2Y12 receptor antagonist;
platelet aggregation inhibitor		201720205.3low000030
l 692585
3
peptide201720205.3high000030
pi103
3
aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor		201720205.3low000030
mer nf5003f
1
202220222.0medium000001
nnc 26-9100
3
aminopyridine201720205.3medium000030
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine
3
201720205.3high000030
tivozanib
3
aromatic ether201720205.3low000030
hki 272
1
nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor		201920195.0low000010
1,2,6,7-tetraoxaspiro(7.11)nonadecane
1
202220222.0low000001
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide
3
201720205.3medium000030
tae226
3
morpholines201720205.3low000030
gw0742
3
monocarboxylic acid201720205.3low000030
u 18666a
3
hydrochlorideantiviral agent;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
Hedgehog signaling pathway inhibitor;
nicotinic antagonist;
sterol biosynthesis inhibitor		201720205.3low000030
sb 525334
3
quinoxaline derivative201720205.3low000030
bx795
3
ureas201720205.3low000030
azd 6244
3
benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor		201720205.3low000030
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea
3
201720205.3medium000030
bay 61-3606
3
pyrimidines201720205.3medium000030
artenimol
4
2008201313.2low000220
sd-208
3
201720205.3low000030
crenolanib
3
aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		201720205.3low000030
aculeatin a
1
202220222.0medium000001
cj 033466
3
201720205.3high000030
cc 401
3
pyrazoles;
ring assembly		201720205.3medium000030
PB28
3
aromatic ether;
piperazines;
tetralins		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist		201720205.3low000030
cariprazine
3
201720205.3low000030
krp-203
3
201720205.3high000030
regorafenib
3
(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor		201720205.3low000030
at 7867
3
monochlorobenzenes;
piperidines;
pyrazoles		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor		201720205.3high000030
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester
3
pyrroloquinoline201720205.3high000030
ptc 124
3
oxadiazole;
ring assembly		201720205.3low000030
degrasyn
2
201920204.5low000020
marizomib
1
beta-lactone;
gamma-lactam;
organic heterobicyclic compound;
organochlorine compound;
salinosporamide		antineoplastic agent;
proteasome inhibitor		2013201311.0low000010
bi 2536
3
201720205.3low000030
azd 1152
3
anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor;
prodrug		201720205.3medium000030
artemisone
1
2013201311.0low000010
carfilzomib
3
epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor		201720205.3low000030
idelalisib
3
aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor		201720205.3low000030
motesanib
3
pyridinecarboxamide201720205.3medium000030
pf-562,271
3
indoles201720205.3medium000030
gliocladin c
3
201720205.3high000030
sb 706504
3
201720205.3high000030
ku-0060648
3
dibenzothiophenes201720205.3medium000030
bgt226
3
aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor		201720205.3medium000030
deoxyartemisinin
2
2007201015.5high000200
cladosporin
1
2013201311.0low000010
n-desmethyldanofloxacin
3
201720205.3high000030
rabeprazole sodium
1
organic sodium salt201720177.0low000010
azd 1152-hqpa
2
anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor		201920204.5low000020
CDN1163
3
aromatic ether;
quinolines;
secondary carboxamide		SERCA activator201720205.3medium000030
amodiaquine hydrochloride
2
2013201311.0low000020
gsk 269962a
3
201720205.3medium000030
pha 848125
3
201720205.3medium000030
nvp-bhg712
3
benzamides201720205.3medium000030
pf 04217903
3
quinolines201720205.3medium000030
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one
3
aromatic ketone201720205.3high000030
ph 797804
3
aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone		anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor		201720205.3low000030
srt1720
3
201720205.3low000030
purfalcamine
3
201720205.3high000030
bms 754807
3
pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		201720205.3low000030
ponatinib
3
(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine		antineoplastic agent;
tyrosine kinase inhibitor		201720205.3low000030
quizartinib
3
benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor		201720205.3low000030
PP121
3
aromatic amine;
cyclopentanes;
pyrazolopyrimidine;
pyrrolopyridine		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
tyrosine kinase inhibitor		201720205.3medium000030
navitoclax
3
aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor		201720205.3low000030
oz 439
10
201120227.9high000082
gsk 650394
3
phenylpyridine201720205.3medium000030
dcc-2036
3
organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines		tyrosine kinase inhibitor201720205.3medium000030
cabozantinib
3
aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor		201720205.3low000030
bix 01294
1
piperidines2013201311.0low000010
TAK-580
3
1,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor		201720205.3medium000030
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one
3
chromones201720205.3high000030
pf 3758309
3
organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound		201720205.3low000030
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
2
benzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
mTOR inhibitor		201920204.5low000020
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
3
aryl sulfide;
thienopyrimidine		201720205.3high000030
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
3
aryl sulfide;
thienopyrimidine		201720205.3high000030
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
3
aryl sulfide;
thienopyrimidine		201720205.3high000030
baricitinib
3
azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent		201720205.3low000030
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine
3
quinazolines201720205.3high000030
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
3
organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound		201720205.3medium000030
sodium artesunate
1
2009200915.0low000100
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide
3
hydroxyquinoline201720205.3high000030
p505-15
3
201720205.3high000030
mrt67307
3
aromatic amine201720205.3medium000030
nitd 609
2
2013201311.0low000020
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide
3
piperazines201720205.3high000030
ribociclib
3
201720205.3low000030
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone
3
aromatic ketone;
thienopyrimidine		201720205.3high000030
pha 793887
3
piperidinecarboxamide201720205.3high000030
gsk 2334470
1
indazoles201920195.0low000010
rka 182
3
201320226.3high000021
ml228 probe
3
1,2,4-triazines;
biphenyls;
pyridines;
secondary amino compound		hypoxia-inducible factor pathway activator201720205.3high000030
pf-03882845
3
201720205.3high000030
jq1 compound
3
carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer		201720205.3low000030
pf-04620110
3
201720205.3medium000030
gsk525762a
3
benzodiazepine201720205.3low000030
birinapant
1
dipeptide201920195.0low000010
torin 1
3
N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines		antineoplastic agent;
mTOR inhibitor		201720205.3medium000030
abt-199
3
aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor		201720205.3low000030
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea
3
ureas201720205.3medium000030
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide
3
(trifluoromethyl)benzenes201720205.3high000030
ncgc00242364
3
quinazolines201720205.3high000030
gsk1210151a
3
imidazoquinoline201720205.3low000030
hs-173
3
201720205.3high000030
sr1664
3
indolecarboxamide201720205.3high000030
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide
3
201720205.3high000030
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide
2
benzamides;
N-acylpiperidine		201720205.5high000020
N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
2
aminoquinoline201720205.5high000020
cudc-907
3
201720205.3low000030
methacycline
1
201920195.0low000010
methacycline monohydrochloride
2
201720205.5low000020
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid
3
quinolines201720205.3high000030
agi-5198
3
201720205.3low000030
cep-32496
3
201720205.3medium000030
epz004777
3
N-glycosyl compound201720205.3low000030
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid
3
organonitrogen heterocyclic compound201720205.3medium000030
entecavir
3
benzamides;
N-acylpiperidine		201720205.3medium000030
gkt137831
3
201720205.3low000030
vx-509
3
201720205.3high000030
vx-970
3
sulfonamide201720205.3low000030
gs-9973
3
201720205.3high000030
amg 925
3
201720205.3high000030
gne-618
3
201720205.3high000030
6-chloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)quinolin-4(1h)-one
1
201620168.0low000010
g007-lk
3
201720205.3medium000030
volitinib
3
201720205.3high000030
ML355
3
benzothiazoles;
monomethoxybenzene;
phenols;
secondary amino compound;
substituted aniline;
sulfonamide		EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
platelet aggregation inhibitor		201720205.3high000030
acp-196
3
aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		201720205.3low000030
gsk343
3
aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor		201720205.3low000030
agi-6780
3
201720205.3medium000030
khs101
3
201720205.3medium000030
cb-839
3
201720205.3low000030
gsk-j4
3
organonitrogen heterocyclic compound201720205.3low000030
pf-06424439
3
201720205.3high000030
etp-46464
3
201720205.3high000030
onc201
3
201720205.3low000030
kai407
3
201720205.3high000030
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine
3
201720205.3high000030
enasidenib
3
1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor		201720205.3low000030
oicr-9429
3
201720205.3medium000030
lly-507
3
201720205.3medium000030
at 9283
3
201720205.3medium000030
hypoxanthine
3
nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite201720205.3low000030
clozapine
3
benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic		201720205.3low000030
1-hydroxyphenazine
3
phenazines201720205.3low000030
ro 24-7429
3
benzodiazepine201720205.3medium000030
nintedanib
3
201720205.3low000030
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide
3
catechols;
hydrazide;
hydrazone;
naphthols		EC 3.6.5.5 (dynamin GTPase) inhibitor201720205.3high000030
ver 52296
3
aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols		angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor		201720205.3low000030
rvx 208
3
201720205.3low000030
bmn 673
3
201720205.3low000030
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
carbamates
1
amino-acid anion2011201113.0low000010
amodiaquine
1
aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug		2012201212.0low000010
chloroquine
5
aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug		2006201613.2low100230
praziquantel
1
isoquinolines201520159.0low000010
pyrimethamine
2
aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor		2006200717.5low000200
adamantane
8
adamantanes;
polycyclic alkane		200820209.8low000260
formal glycol
1
cyclic acetal;
dioxolane		2013201311.0low000010
artemisinin
7
organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite		2004201714.6low000430
artemether
5
artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial2006201613.8low100320
atovaquone
1
hydroxy-1,2-naphthoquinone2007200717.0low000100
artesunic acid
4
2006201414.2low000220
piperaquine
11
aminoquinoline;
N-arylpiperazine;
organochlorine compound		antimalarial200720219.5low600272
furamidine
2
2006200817.0low000200
puromycin
1
puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor		201520159.0low000010
thapsigargin
1
butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor		2013201311.0low000010
artemisin
1
2010201014.0low000100
sesquiterpenes
6
2004200718.5low000600
tempo
1
aminoxyls;
piperidines		catalyst;
ferroptosis inhibitor;
radical scavenger		2010201014.0low000100
lumefantrine
1
fluorenes;
monochlorobenzenes;
secondary alcohol;
tertiary amine		antimalarial201620168.0low100010
cgp-56697
2
201720215.0low200011
artenimol
3
2012201610.0low000030
artemisone
2
2012201411.0low000020
mefloquine
2
202120213.0low100002
1,2,4-trioxane
4
200820209.2low000130
oz 439
6
201220208.0medium000060
deoxyartemisinin
2
2007201015.5medium000200
hypoxanthine
1
nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite2013201311.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
African Sleeping Sickness0
1
2009200915.0low000100
Disease Models, Animal0
3
2007201810.7low000120
Infections, Plasmodium0
15
2004202212.1high200681
Malaria0
15
2004202212.1high200681
Malaria, Falciparum0
12
2007202110.7medium700462
Malaria, Vivax0
2
2006201613.0low100110
Parasitemia0
2
2006200717.5low000200
Plasmodium falciparum Malaria0
12
2007202110.7medium700462
Plasmodium vivax Malaria0
2
2006201613.0low100110
Schistosoma mansoni Infection0
1
201520159.0low000010
Schistosomiasis mansoni0
1
201520159.0low000010
Sensitivity and Specificity0
1
2009200915.0low000100
Trypanosomiasis, African0
1
2009200915.0low000100

Safety/Toxicity (6)

ArticleYear
Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate in comparison with chloroquine phosphate in children with acute uncomplicated
Journal of vector borne diseases, , Volume: 57, Issue:3
Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Rando
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Oct-30, Volume: 65, Issue:10		2017
Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study.
Malaria journal, , Jan-27, Volume: 15		2016
Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study.
Malaria journal, , Nov-25, Volume: 14		2015
Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects.
Journal of clinical pharmacology, , Volume: 54, Issue:4		2014
Comparative embryotoxicity of different antimalarial peroxides: in vitro study using the rat whole embryo culture model (WEC).
Reproductive toxicology (Elmsford, N.Y.), , Volume: 30, Issue:4		2010

Pharmacokinetics (3)

ArticleYear
Endoperoxide Drug Cross-Resistance Patterns for Plasmodium falciparum Exhibiting an Artemisinin Delayed-Clearance Phenotype.
Antimicrobial agents and chemotherapy, , Volume: 60, Issue:11		2016
Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects.
Journal of clinical pharmacology, , Volume: 54, Issue:4		2014
Pharmacokinetics and pharmacodynamics of arterolane maleate following multiple oral doses in adult patients with P. falciparum malaria.
Journal of clinical pharmacology, , Volume: 51, Issue:11		2011

Bioavailability (3)

ArticleYear
Highly predictive and interpretable models for PAMPA permeability.
Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3		2017
Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study.
Malaria journal, , Jan-27, Volume: 15		2016
Identification of an antimalarial synthetic trioxolane drug development candidate.
Nature, , Aug-19, Volume: 430, Issue:7002		2004

Dosage (2)

ArticleYear
Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Rando
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Oct-30, Volume: 65, Issue:10		2017
Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects.
Journal of clinical pharmacology, , Volume: 54, Issue:4		2014